On Monday, Eli Lilly And Co (NYSE:LLY) announced results from two Phase 3 studies of mirikizumab across two types of inflammatory bowel diseases (IBD). The studies showed patients treated with ...

Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of ...

Lymphocytic colitis is a type of microscopic colitis that causes persistent, watery diarrhea. Experts still do not know the exact underlying cause. Microscopic colitis involves inflammation of the ...

At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel ...

After its $7.2 billion buyout of Receptos, Celgene ($CELG) has posted some encouraging midstage data for its acquired asset ozanimod for certain forms of inflammatory ...

Since hitting the market in 2009, Johnson & Johnson’s blockbuster drug Stelara has made a habit of exceeding analyst expectations. There was no better example than last year when it overcame ...

Learn about the potential benefits of the Mediterranean diet for managing ulcerative colitis, including lower inflammation and improved gut health, with expert tips.

Edda Ramsdell, the executive director of CCFA’s Long Island Chapter Colin Quinn, comedic star of stage, screen and TV, will highlight the evening’s entertainment at the Crohn’s & Colitis Foundation of ...